drugset
drugset / Trial / NCT01177150

A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers

NCT01177150 ↗

Phase 1 Completed 71 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and or the pharmacodynamics (PD) of single oral doses of JNJ-28431754 in healthy male volunteers. The study will evaluate the PK and PD effects of study drug in volunteers who fasted compared to those who did not fast before study drug administration.

Timeline

Start
2006-11
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 10 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 600 mg Oral

Indications

No indication recorded.